CGON — CG Oncology, Inc. Common stock
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 113
- Website: https://cgoncology.com
Latest SEC filings for CGON
- 3 — 2026-10-19
- SCHEDULE 13G/A — 2026-08-14
- SCHEDULE 13G/A — 2026-08-14
- 424B5 — 2026-08-06
- 10-Q — 2026-08-06
- 8-K — 2026-08-06
- 424B5 — 2026-08-06
- 8-K — 2026-06-08
- 8-K — 2026-05-26
- SCHEDULE 13G — 2026-05-15
Latest CGON news
- — CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer (globenewswire.com)
- — Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm (gurufocus.com)
- — Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm (prnewswire.com)
Educational tool only — not investment advice.